Genetic studies of myeloid and lymphoid malignancy studies in china (CAS: 10512) in support of the department of health and human services (DHHS), national institutes of health (NIH), national…

Ended Purchase Order Awarded Last action

Contract number
75N91019P00780
Awardee
Awarding agency
Obligated
$114,966

Award facts

Opportunity
Contract value 100% obligated
$114,966.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Not Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
China

Award details come from SAM.gov/FPDS.

About this award

The National Cancer Institute issued a purchase order to Gene Square Bio-Technology LTD. for $114,966.00 on September 16, 2019, for genetic studies of myeloid and lymphoid malignancy in China. Work is performed in China. The order is firm fixed price with an ultimate completion date of September 15, 2020. The requirement originated from a special notice posted July 23, 2019, with a due date of July 31, 2019.

Description

Genetic studies of myeloid and lymphoid malignancy studies in china (CAS: 10512) in support of the department of health and human services (DHHS), national institutes of health (NIH), national cancer institute (NCI),division of cancer epidemiology an

Quick answers

Who was awarded contract 75N91019P00780?

75N91019P00780 was awarded to Gene Square Bio-Technology LTD. by National Cancer Institute (National Institutes of Health) on September 16, 2019.

How much is contract 75N91019P00780 worth?

The government has obligated $114,966 on 75N91019P00780.

Was contract 75N91019P00780 competed?

The extent of competition for 75N91019P00780 was not competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award